– Clinical and preclinical data support Seres’ development of microbiome therapeutics to reduce the incidence of antibiotic-resistant bacterial infections –

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Matthew Henn, Ph.D., Chief Scientific Officer at Seres, will be presenting at the World Anti-Microbial Resistance Congress being held on September 7-8, 2022 in National Harbor, Maryland. Dr. Henn will present at 12:00 p.m. ET today a presentation entitled: “Microbiome Therapeutics to Potentially Transform the Management of Antimicrobial Resistant Infections.” The presentation will review additional Phase 3 clinical data indicating that SER-109 engraftment reduced pathogens that can harbor antimicrobial resistance genes and preclinical data supporting the development of SER-155 for targeting bacterial antimicrobial resistant (AMR) infections in medically compromised patient populations.

“Antibiotic-resistant bacterial infections are a significant public health concern and represent an all too frequent life-threatening complication in individuals requiring allogeneic hematopoietic stem cell transplantation, facing cancer, and other immunocompromised groups,” said Dr. Henn. “Seres’ clinical and preclinical data suggest that microbiome therapeutics may provide a novel approach to reduce the risk of antibiotic-resistant bacterial infection. We hope to meaningfully improve outcomes in multiple medically compromised patient populations, such as cancer neutropenia, cirrhosis, and solid organ transplant, that have limited treatment options for AMR infections and bacteremia.”

Seres’ approach developing microbiome therapeutics for Infection Protection has been clinically validated by the Company’s SER-109 program, an investigational product for the prevention of recurrent C. difficile infection. Supported by a completed Phase 3 development program, a SER-109 Biologics License Application (BLA) has been filed with U.S. Food and Drug Administration (FDA) and the commercial launch is anticipated in the first half of 2023. Building upon SER-109 clinical data, Seres is evaluating SER-155 in an ongoing Phase 1b study in individuals undergoing allogeneic hematopoietic stem cell transplantation and at elevated risk of life-threatening Vancomycin-Resistant Enterococcus (VRE) and Carbapenem-Resistant Enterobacteriaceae (CRE) infections. Seres is also developing additional preclinical stage programs targeting Infection Protection in medically compromised patients.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced to prevent further recurrences of C. difficile infection and has potential to become a first-in-class FDA-approved oral microbiome therapeutic. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.

For more information, please visit www.serestherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the potential approval and launch of SER-109 and its status as a first-in-class therapeutic; the potential impact of microbiome therapeutics in Infection Protection; and other statements which are not historical fact.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; the impact of the COVID-19 pandemic; our unproven approach to therapeutic intervention; the lengthy, expensive and uncertain process of clinical drug development; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates and develop and commercialize our product candidates, if approved; and our ability to retain key personnel and to manage our growth. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), on August 3, 2022, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005281/en/